Universität zu Köln

Breyer, Johannes, Wirtz, Ralph M., Otto, Wolfgang, Erben, Philipp ORCID: 0000-0002-8279-7636, Worst, Thomas S., Stoehr, Robert, Eckstein, Markus, Denzinger, Stefan, Burger, Maximilian and Hartmann, Arndt (2018). High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients. Cancer Immunol. Immunother., 67 (3). S. 403 - 413. NEW YORK: SPRINGER. ISSN 1432-0851

Full text not available from this repository.

Abstract

Introduction and objectives Checkpoint inhibition has emerged as new therapeutic option in muscle-invasive bladder cancer. The objective of the present study was to evaluate the prognostic role of PD1 and PDL1 expression in non-muscle-invasive bladder cancer (NMIBC) and establish an objective measuring method using RNA quantification. Materials and methods We retrospectively analyzed clinical data and formalin-fixed paraffin-embedded tissues (FFPE) of patients with stage pT1 NMIBC who underwent transurethral resection of the bladder. mRNA expression of PD1, PDL1 and CD3 was measured by single step RT-qPCR and correlated to clinicopathological parameters, recurrence-free survival (RFS), progression-free survival (PFS) and carcinoma-specific survival (CSS). Results We have analyzed 334 patients with NMIBC at stage pT1 for mRNA analysis. Data from 296 patients (79% male, median age: 72 years) could be used. Spearman correlation revealed significant associations between mRNA expressions of PD1/PDL1 (rho: 0.6024, p < 0.0001), CD3/PDL1 (rho: 0.5728, p < 0.0001) and CD3/PD1 (rho: 0.7005, p < 0.0001). Kaplan-Meier analysis revealed that high PDL1 mRNA expression (>= 33.83) is a favorable prognostic factor with regard to better RFS (p = 0.0018), PFS (p = 0.021) and CSS (p = 0.012). Multivariate Cox-regression analysis proved PDL1 expression to be an independent prognosticator for RFS [HR 0.48 (0.31-0.72), p = 0.0005], PFS [HR 0.45 (0.24-0.80), p = 0.0059] and CSS [HR 0.31 (0.13-0.67), p = 0.0021]. Conclusion High mRNA expression of PDL1 predicts improved RFS, PFS and CSS of pT1 NMIBC. Following prospective validation, this objective measurement of PD-L1 might help stratify patients with NMIBC for immunotherapy and identify patients who might benefit from early cystectomy.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Breyer, Johannes UNSPECIFIED UNSPECIFIED UNSPECIFIED Wirtz, Ralph M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Otto, Wolfgang UNSPECIFIED UNSPECIFIED UNSPECIFIED Erben, Philipp UNSPECIFIED orcid.org/0000-0002-8279-7636 UNSPECIFIED Worst, Thomas S. UNSPECIFIED UNSPECIFIED UNSPECIFIED Stoehr, Robert UNSPECIFIED UNSPECIFIED UNSPECIFIED Eckstein, Markus UNSPECIFIED UNSPECIFIED UNSPECIFIED Denzinger, Stefan UNSPECIFIED UNSPECIFIED UNSPECIFIED Burger, Maximilian UNSPECIFIED UNSPECIFIED UNSPECIFIED Hartmann, Arndt UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-193209
DOI:	10.1007/s00262-017-2093-9
Journal or Publication Title:	Cancer Immunol. Immunother.
Volume:	67
Number:	3
Page Range:	S. 403 - 413
Date:	2018
Publisher:	SPRINGER
Place of Publication:	NEW YORK
ISSN:	1432-0851
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language UROTHELIAL CARCINOMA; BREAST-CANCER; PD-L1 EXPRESSION; CELL; B7-H1; IMMUNOTHERAPY; ASSOCIATION; RECURRENCE Multiple languages Oncology; Immunology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/19320